Conjupri (levamlodipine) NDC 24075-0411

NDC codes

FDA NDC Directory

Product NDC (as listed)24075-0411Labeler and product segments. Claims need a package NDC.

Product NDC at billing width24075-0411Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
24075-0411-3	24075041103	2.5 mg in 1 BOTTLE (24075-0411-3)Marketed from Oct 8, 2021
24075-0411-5	24075041105	2.5 mg in 1 BOTTLE (24075-0411-5)Marketed from Oct 8, 2021
24075-0411-9	24075041109	2.5 mg in 1 BOTTLE (24075-0411-9)Marketed from Oct 8, 2021

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Conjupri
Generic name (nonproprietary): levamlodipine
Active ingredients: Levamlodipine maleate — 2.5 mg/2.5mg
Dosage form: Tablet
Route: Oral
Labeler: CSPC Ouyi Pharmaceutical Co. Ltd
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 212895
Marketing start: Oct 8, 2021
Listing expires: Dec 31, 2026
Identifiers: Product ID 24075-0411_22836378-d73e-4b0b-88bb-b82dd3420aabSPL ID 22836378-d73e-4b0b-88bb-b82dd3420aabSPL set ID c3cca66e-348a-43e8-8f96-e995104dae3dRxCUI 2377367, 2377369, 2377371, 2377373UNII 12WW9T2ITAUPC 0324075041158, 0324075041257

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N424075041103 followed by a unit qualifier and the quantity

Package 24075-0411-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 11, 2024.

Indications (excerpt from the label)

CONJUPRI ® is calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. 1.1 Hypertension CONJUPRI ® is indicated for the treatment of hypertension in adults and patients 6 years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharm…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 212895

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 212895
Product	Strength	Form · route	Labeler	Product NDC
Conjuprilevamlodipine	Levamlodipine maleate 5 mg/5mg	TabletOral	CSPC Ouyi Pharmaceutical Co. Ltd	24075-0413